Literature DB >> 17970741

A natural antisense transcript against Rad18, specifically expressed in neurons and upregulated during beta-amyloid-induced apoptosis.

Rosalba Parenti1, Sabrina Paratore, Antonietta Torrisi, Sebastiano Cavallaro.   

Abstract

Apoptosis, the main form of programmed cell death, is associated to a complex and dynamic transcriptional and post-transcriptional programme. By microarray analysis, we have previously implicated 241 genes differentially expressed in rat cortical neurons exposed to beta-amyloid (Abeta) protein, the major constituent of amyloid plaques in Alzheimer's disease. A large number of identified genes have no name or known function. In the present study, we have investigated one of these genes that encodes for a natural antisense transcript against Rad18 (NAT-Rad18). Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) confirmed differential expression of this transcript in cortical neurons exposed to Abeta. In situ hybridization, qRT-PCR and immunohistochemistry were used to assess the regional and cellular distribution of NAT-Rad18 in adult rat brain. These experiments showed a widespread distribution of NAT-Rad18, with the highest levels in the cerebellum, brainstem and cortex, where it was specifically expressed by neurons. NAT-Rad18 was also strongly expressed in epithelial cells of choroid plexus and cerebral vessels. At the cellular level, expression of Rad18 was counterbalanced by that of its natural antisense transcript, as shown by both in situ hybridization and immunohistochemistry. These experiments suggest the existence of a NAT that exerts a post-transcriptional control over Rad18.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17970741     DOI: 10.1111/j.1460-9568.2007.05864.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  31 in total

Review 1.  Targeting long non-coding RNA to therapeutically upregulate gene expression.

Authors:  Claes Wahlestedt
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

Review 2.  The Role of Long Noncoding RNAs in Neurodegenerative Diseases.

Authors:  Peixing Wan; Wenru Su; Yehong Zhuo
Journal:  Mol Neurobiol       Date:  2016-02-24       Impact factor: 5.590

3.  Pseudogenes as an alternative source of natural antisense transcripts.

Authors:  Enrique M Muro; Miguel A Andrade-Navarro
Journal:  BMC Evol Biol       Date:  2010-11-03       Impact factor: 3.260

Review 4.  Invited Review: Long non-coding RNAs: important regulators in the development, function and disorders of the central nervous system.

Authors:  R Cuevas-Diaz Duran; H Wei; D H Kim; J Q Wu
Journal:  Neuropathol Appl Neurobiol       Date:  2019-03-04       Impact factor: 8.090

5.  Age-Related Expression of a Repeat-Rich Intergenic Long Noncoding RNA in the Rat Brain.

Authors:  Sukhleen Kour; Pramod C Rath
Journal:  Mol Neurobiol       Date:  2016-01-11       Impact factor: 5.590

6.  Natural antisense transcripts as therapeutic targets.

Authors:  Paul Halley; Olga Khorkova; Claes Wahlestedt
Journal:  Drug Discov Today Ther Strateg       Date:  2013

Review 7.  Noncoding RNAs in Alzheimer's disease.

Authors:  M Laura Idda; Rachel Munk; Kotb Abdelmohsen; Myriam Gorospe
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-01-12       Impact factor: 9.957

8.  Cutting edge: MHC class I-Ly49 interaction regulates neuronal function.

Authors:  Ofer Zohar; Yoram Reiter; Jack R Bennink; Avital Lev; Sebastiano Cavallaro; Sabrina Paratore; Chaim G Pick; Gary Brooker; Jonathan W Yewdell
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

9.  Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain.

Authors:  Neil R Smalheiser; Giovanni Lugli; Vetle I Torvik; Nathan Mise; Rieko Ikeda; Kuniya Abe
Journal:  Neurosci Res       Date:  2008-09-04       Impact factor: 3.304

Review 10.  Molecular landscape of long noncoding RNAs in brain disorders.

Authors:  Sumin Yang; Key-Hwan Lim; Sung-Hyun Kim; Jae-Yeol Joo
Journal:  Mol Psychiatry       Date:  2020-11-10       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.